oxytocin

Ligand id: 2174

Name: oxytocin

Abbreviated name: OT

Species: Human, Mouse, Rat

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: oxytocin

Structure and Physico-chemical Properties

2D Structure
References
1. Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M. (1999)
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
Br J Obstet Gynaecol106: 1047-1053. [PMID:10519430]
2. Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S et al.. (1995)
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
EMBO J.14 (10): 2176-82. [PMID:7774575]
3. Chini B, Mouillac B, Balestre M-N, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C. (1996)
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin.
FEBS letters.397: 201-206. [PMID:8955347]
4. Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, Golzio L, Marinelli P, Thomas RJ, Chevillard C, Laurent F, Portet K, Barberis C, Chollet A. (2003)
Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
J Pharmacol Exp Ther306: 253-261. [PMID:12660315]
5. Griffante C, Green A, Curcuruto O, Haslam CP, Dickinson BA, Arban R. (2005)
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
Br J Pharmacol146: 744-751. [PMID:16158071]
6. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ. (1995)
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
Life Sci57: 2253-2261. [PMID:7475979]
7. Phalipou S, Cotte N, Carnazzi E, Seyer R, Mahe E, Jard S, Barberis C. (1997)
Mapping peptide binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
J Biol Chem272: 26536-26544. [PMID:9334232]
8. Saito M, Tahara A, Sugimoto T. (1997)
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
Biochem Pharmacol53: 1711-1717. [PMID:9264324]
9. Tahara A, Saito M, Sugimoto J, Tomura Y, Wada KI, Kusayama T, Tsukada J, Ishii I, Yatsu T, Uchida W, Tanaka A. (1998)
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in chinese hamster ovary cells.
Br J Pharmacol125: 1463-1470. [PMID:9884074]
10. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A. (1998)
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Naunyn Schmiedebergs Arch Pharmacol357: 63-69. [PMID:9459574]
11. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. (1994)
Molecular cloning, sequencing, and functional expression of a cDNA encoding thehuman V1a vasopressin receptor.
J Biol Chem269: 3304-3310. [PMID:8106369]
12. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Matera LN, Mattera R. (1997)
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
Endocrinology.138: 4109-4122. [PMID:9322919]